NEWS FROM SEDIA BIOSCIENCES
Sedia Biosciences Announces ISO 13485 Certification for Production of HIV In Vitro Diagnostics Tests
Sedia Biosciences Corporation today announced that it has received ISO 13485:2016 Certification of its Beaverton, OR facilities for the production and distribution of two of its key Products. ISO 13485 is an internationally recognized quality standard for medical devices and Certification was provided by TÜV SÜD Product Service GmbH, of Munich Germany, an International Organization for Standardization (ISO) Certification Body.
Sedia Announces COVID-19 Whole Genome Sequencing Service for Novel Variant Detection, Surveillance
Sedia Biosciences Corporation today announced the launch of a new service, “Sedia® COVID-19 WGS”, offering whole genome sequencing of SARS-CoV-2 samples for novel variant detection and surveillance.
Sedia Biosciences Board Announces Changes to Executive Leadership
The Board of Directors of Sedia Biosciences Corporation today announced a series of changes to the Company’s executive management team.
Sedia Biosciences Announces Expansion and Move to New Research and Manufacturing Facility
Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities.
News Coverage: Sedia Biosciences receives matching SBIR grant from Business Oregon
Business Oregon, an Oregon state agency, announces the award of a $146,630 SBIR matching grant from Business Oregon to support scale-up of our Asanté ® HIV-1 Rapid Recency® Assay and the hire and training of manufacturing and quality control staff.
News Coverage: Portland biotech startup foresees rapid growth from HIV test
Sedia Biosciences has laid the groundwork with its test that determines how recently someone has been infected with HIV. Its new test will be able to give the result in just 20 minutes.
Sedia Biosciences and Floragenex Announce Completion of Merger
Sedia Biosciences Corporation (Portland, OR) and Floragenex Inc. (Eugene, OR) today announced the merger of their companies. Sedia will continue the business of Floragenex as a wholly-owned subsidiary with current Floragenex Chief Executive Officer, Dr. Rick Nipper continuing oversight of the new subsidiary.
Sedia Biosciences Awarded Additional $1.8 M NIH Grant for Novel Rapid HIV Test for Recent Infections
Sedia Biosciences Corporation has received notification from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) of the award of a $1.8 Million Phase II Small Business Innovation Research (SBIR) Grant to accelerate development of Sedia’s Asanté ® HIV-1 Rapid Recency™ Assay.
Sedia Expands Its HIV-1 LAg-Avidity Assay for Recent HIV-1 Infections to Dried Blood Spot Specimens
The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a leading HIV incidence assay, can now be used on dried blood specimens without need for cold chain storage.
Independent Study Shows Sedia’s New HIV-1 LAg-Avidity Test is Top Performing Incidence Assay
CEPHIA comparative evaluation demonstrates that Sedia assay has lowest false recency rate.
CONTACT US
Want to know more or have any questions? Send us a message!